(Q44688774)

5 December 2017

title

Treatment of Mycobacterium chelonae-induced skin infection with clarithromycin (English)

1 reference

5 December 2017

main subject

Mycobacterium chelonae

1 reference

1 reference

2

1 reference

5 December 2017

Franck N

1

1 reference

5 December 2017

Villette B

3

1 reference

5 December 2017

Amor B

4

1 reference

5 December 2017

Lessana-Leibowitch M

5

1 reference

5 December 2017

Escande JP

6

1 reference

5 December 2017

language of work or name

English

0 references

publication date

1 June 1993

1 reference

Journal of the American Academy of Dermatology

5 December 2017

published in

1 reference

5 December 2017

volume

28

1 reference

5 December 2017

issue

6

1 reference

5 December 2017

page(s)

1019-1021

1 reference

Anonymous mycobacteria in pulmonary disease

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2808%2980660-3

7 January 2021

Mycobacterium chelonae wound infections after plastic surgery employing contaminated gentian violet skin-marking solution

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2808%2980660-3

7 January 2021

Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2808%2980660-3

7 January 2021

Mycobacterium chelonaeCausing Otitis Media in an Ear-Nose-and-Throat Practice

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2808%2980660-3

7 January 2021

Sporotrichoid cutaneous infection due to Mycobacterium chelonei in a renal transplant patient

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2808%2980660-3

7 January 2021

Adjunctive surgical management of cutaneous Mycobacterium fortuitum infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2808%2980660-3

7 January 2021

Treatment of Mycobacterium chelonae infection with controlled localized heating

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2808%2980660-3

7 January 2021

Treatment of disseminated Mycobacterium chelonae infection with ciprofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2808%2980660-3

7 January 2021

In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2808%2980660-3

7 January 2021

In vitro activity of four fluoroquinolones against eighty-six isolates of mycobacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2808%2980660-3

7 January 2021

In vitro activity of clofazimine against rapidly growing nonchromogenic mycobacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2808%2980660-3

7 January 2021

Clinical Usefulness of Amikacin and Doxycycline in the Treatment of Infection Due to Mycobacterium fortuitum and Mycobacterium chelonei

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2808%2980660-3

7 January 2021

Rapidly growing mycobacteria: testing of susceptibility to 34 antimicrobial agents by broth microdilution

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2808%2980660-3

7 January 2021

In vitro susceptibility of Mycobacterium fortuitum and Mycobacterium chelonei to sulfadiazine, sulfisoxazole and sulfathiazole

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2808%2980660-3

7 January 2021

Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2808%2980660-3

7 January 2021

The pharmacokinetics of clarithromycin and its 14-OH metabolite

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2808%2980660-3

7 January 2021

The diffusion of clarithromycin and roxithromycin into nasal mucosa, tonsil and lung in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2808%2980660-3

7 January 2021

An in-vitro evaluation of the cellular uptake and intraphagocytic bioactivity of clarithromycin (A-56268, TE-031), a new macrolide antimicrobial agent

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2808%2980660-3

7 January 2021

Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2808%2980660-3

7 January 2021

Comparative in vitro activity of the new macrolide A-56268 against mycobacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2808%2980660-3

7 January 2021

10.1016/S0190-9622(08)80660-3

Identifiers

DOI

1 reference

5 December 2017

1 reference